ranolazine has been researched along with Disease Exacerbation in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J | 1 |
| Bontempi, L; Cerini, M; Curnis, A; Giacopelli, D; Inama, L; Raweh, A; Salghetti, F; Sciatti, E; Vassanelli, F; Villa, C; Vizzardi, E | 1 |
| Aistrup, GL; Belardinelli, L; Beussink, L; Chirayil, N; El-Bizri, N; Gupta, DK; Kelly, JE; Misener, S; Mongkolrattanothai, T; Nahhas, A; Ng, J; O'Toole, MJ; Rajamani, S; Reddy, M; Shah, SJ; Shryock, JC; Singh, N; Wasserstrom, JA | 1 |
| Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC | 1 |
| Arnold, SV; Braunwald, E; Cohen, DJ; Lei, Y; Mahoney, EM; Morrow, DA; Scirica, BM; Wang, K | 1 |
| Zaza, A | 1 |
| Castellino, FJ; Gutierrez, LS; Navari, RM; Paoni, NF; Pollard, M; Risatti, CA; Suckow, MA; Taylor, RE; Wolter, WR | 1 |
1 review(s) available for ranolazine and Disease Exacerbation
| Article | Year |
|---|---|
[The late sodium current: pathophysiology and pharmacology of a new therapeutic target].
Topics: Acetanilides; Arrhythmias, Cardiac; Disease Progression; Enzyme Inhibitors; Heart Conduction System; Heart Diseases; Humans; Muscle Cells; Myocardial Contraction; Myocardial Ischemia; Piperazines; Ranolazine; Sodium; Sodium Channels; Treatment Outcome | 2011 |
1 trial(s) available for ranolazine and Disease Exacerbation
| Article | Year |
|---|---|
Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Angina, Unstable; Disease Progression; Double-Blind Method; Dyspnea; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quality of Life; Ranolazine; Surveys and Questionnaires | 2008 |
5 other study(ies) available for ranolazine and Disease Exacerbation
| Article | Year |
|---|---|
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome | 2020 |
Ranolazine therapy in drug-refractory ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Defibrillators, Implantable; Disease Progression; Drug Resistance; Electric Countershock; Female; Heart Failure; Humans; Male; Middle Aged; Ranolazine; Recurrence; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Fibrillation | 2017 |
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.
Topics: Acetanilides; Animals; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger; Time Factors; Ultrasonography | 2013 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Enalapril; Heart Failure; Metoprolol; Myocardium; Piperazines; Proteins; Ranolazine; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
Topics: Acetanilides; Adenomatous Polyposis Coli; Alleles; Animals; Carcinogens; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, APC; Injections, Intraperitoneal; Intestinal Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Invasiveness; Piperazines; Ranolazine | 2004 |